|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Stalevo[始立] information |
|
|
|
製造商 |
Novartis |
|
代理/經銷商 |
Novartis |
|
成份 |
Per 50/12.5/200 mg tab Levodopa 50 mg, carbidopa 12.5 mg, entacapone 200 mg. Per 100/25/200 mg tab Levodopa 100 mg, carbidopa 25 mg, entacapone 200 mg. Per 150/37.5/200 mg tab Levodopa 150 mg, carbidopa 37.5 mg, entacapone 200 mg. Per 200/50/200 mg tab Levodopa 200 mg, carbidopa 50 mg, entacapone 200 mg |
|
適應症 |
Treatment of Parkinson's disease & end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment. |
|
用量 |
1 tab/dose administration. Max: Entacapone 2,000 mg or 10 tab/day. Dose adjustment of other antiparkinsonian drugs may be necessary when Stalevo is started in patient not receiving entacapone. |
|
過量 |
View Stalevo[始立] overdosage for action to be taken in the event of an overdose. |
|
用法 |
May be taken with or without food |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
Severe hepatic impairment, narrow-angle glaucoma, pheochromocytoma, concomitant use of selective & nonselective MAO-A & MAO-B inhibitor, history or neuroleptic malignant syndrome &/or non-traumatic rhabdomyolysis. |
|
注意事項 |
Not recommended for the treatment of drug-induced extrapyramidal symptoms. Severe cardiovascular or pulmonary disease, bronchial asthma, renal, hepatic or endocrine disease, chronic wide-angle glaucoma; history of peptic ulcer disease, convulsions, MI, ventricular arrhythmias, past or current psychosis, in the event of general anaesth, extended therapy or when discontinuing treatment. Development of mental changes, depression with suicidal tendencies, & other serious antisocial behaviour should be monitored carefully. Pregnancy, lactation. May impair ability to drive or operate machinery. Not recommended in patients < 18 years. |
|
不良反應 |
Haemolytic anaemia, neuroleptic malignant syndrome, agranulocytosis, hepatitis, malignant melanoma, sudden sleep onset episodes, mental changes including paranoid ideation & psychotic episodes, depression with or without suicidal tendencies, dyskinesia, Parkinsonism aggravated, dizziness, dystonia, hyperkinesia, insomnia, hallucinations, confusion, paroniria, duodenal ulcer, GI bleeding, GI disturbances, discoloration of urine, fatigue, increased sweating, fall.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Antihypertensives, MAO-A inhibitors, tricyclic antidepressants or noradrenaline reuptake inhibitors. Co-administration of selegiline should not exceed 10 mg/day. Dopamine receptor antagonists (e.g. some antipsychotics & antiemetics), phenytoin & papaverine. A control of INR is recommended for patients receiving warfarin. Fe prep, high protein diet.
View more drug interactions with Stalevo[始立] |
|
儲存 |
View Stalevo[始立] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Stalevo[始立] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Stalevo[始立] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Stalevo 50/12.5/200 mg 膜衣錠 |
|
|
Stalevo 100/25/200 mg 膜衣錠 |
|
|
Stalevo 150/37.5/200 mg 膜衣錠 |
|
|
Stalevo 200/50/200 mg 膜衣錠 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Novartis |
|
 |
|
|
|
